|Bid||8.03 x 1200|
|Ask||10.15 x 800|
|Day's Range||8.10 - 8.47|
|52 Week Range||6.76 - 13.99|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.67|
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update.